SEROMETRIX is Redefining Drug Discovery

A biotechnology target and lead discovery and optimization company, Serometrix is delivering better answers by asking better questions. Seeking a way to shorten development times and improve yields, the company developed SimPep™, the company's in silico discovery platform, to probe nature in novel ways to:

  • Identify relevant protein-protein interaction sites critical to regulating pathways integral to biological conditions of commercial interest
  • Emulate these highly evolved human regulatory sequences (7-10 amino acids) in confirmatory in vitro assays
  • Optimize these novel hits using structure based optimization techniques

Utilizing this platform, Serometrix harnesses the clinically predictive power inherent within the human system; the only rational approach that promises to immediately and dramatically enhance productivity in drug development.

 

Intelligently probing the human proteome for novel answers to complex regulatory questions. Serometrix provides clinical predictability via the discovery and subsequent emulation and optimization of highly evolved human protein segments.